Research

*January 2023* The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies -- DESTINY-Lung01 and CodeBreaK100 -- incorporated into the guidance. In the update, published in the Journal of Clinical Oncology, Dwight H. Owen, MD, MS, of the Ohio State University in Columbus,…

*November 2022* Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the most impressive efficacy and is a potential new standard of care. Drug-related interstitial lung disease remains a serious unpredictable…

*December 2022* In non–small cell lung cancer, EGFR mutations, MET exon 14 skipping mutations, and HER2 mutations are common mutations for which directed therapies are available. New approaches and novel agents are constantly being developed to identify and treat emerging targets in non– small cell lung cancer (NSCLC). This article…

*October 2022* Introduction There is a paucity of data on immune checkpoint inhibitors (ICIs) plus doublet chemotherapy (C) in patients with advanced lung cancer whose tumor harbors an actionable mutation. We sought to provide insight into the role of this combination in relation to chemotherapy alone in this patient population.…

*December 2022* This video presentation features perspectives from lung cancer experts Drs Alexander Spira and Helena Yu and discusses the following: What is an antibody-drug conjugate? HER-2 positive NSCLC Targeting HER3 NSCLC TROP2-directed treatment Novel Agents Watch video here.

*December 2022* Newly diagnosed patients with non-small cell lung cancer (NSCLC) benefit tremendously from next-generation sequencing (NGS) to test for driver mutations and determine the best first-line treatment. But NGS platforms, such as parallel DNA sequencing, can have longer turnaround times than non-NGS testing, and "elays in time to treatment…

*December 2022* The treatment of LUAD-LM is particularly challenging and intrathecal pemetrexed is a potential therapeutic strategy for it, but still faces many obstacles caused by repeated lumbar puncture. We performed a prospective phase I study on 33 refractory LUAD-LM patients, aimed at assessing the safety, pharmacokinetic and clinical activity…

*December 2022* Take a behind-the-scenes look at how researchers study lung cancer. Join lung cancer researcher Dr. Triparna Sen as she digs into what’s known about how EGFR-positive NSCLC cells transform into SCLC to escape targeted therapy treatment. SCLC transformation is a common resistance mechanism for multiple types of NSCLC,…

*November 2022* Melina E. Marmarelis, MD, medical director of Penn Medicine Mesothelioma and Pleural Program and assistant professor of medicine at the Hospital of the University of Pennsylvania, reports the rationale and key findings from the Chrysalis-2 trial (NCT04077463) of patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC). A cohort…

*November 2022* The combination of tepotinib (Tepmetko) and gefitinib (Iressa) demonstrated an improvement in both progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with EGFR-mutant non–small cell lung cancer (NSCLC) who developed MET-driven resistance to prior EGFR tyrosine kinase inhibitors (TKIs), according to findings from the final analysis of…